Dasatinib Anhydrous
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. [ ]
Term info
Dasatinib Anhydrous
- DASATINIB ANHYDROUS
- Dasatinib Anhydrous
NCIT_C63923
302962-49-8
CHEBI:49375
C22H26ClN7O2S
X78UG0A0RN
http://purl.obolibrary.org/obo/NCIT_C26156, http://purl.obolibrary.org/obo/NCIT_C17328, http://purl.obolibrary.org/obo/NCIT_C16325, http://purl.obolibrary.org/obo/NCIT_C17528, http://purl.obolibrary.org/obo/NCIT_C30164
Dasatinib_Anhydrous
Dasatinib Anhydrous
Pharmacologic Substance
C2699562
C74556
Term relations
- BCR-ABL Inhibitor
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Receptor Tyrosine Kinase Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Inhibition of Cell Proliferation
- Chemical_Or_Drug_Has_Physiologic_Effect some Signal Transduction Inhibition
- Chemical_Or_Drug_Affects_Gene_Product some SRC Family Tyrosine Kinase
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis